JP2013510106A - 乳酸脱水素酵素（ｌｄｈ）の阻害化合物およびこれらの化合物を含む医薬組成物 - Google Patents
乳酸脱水素酵素（ｌｄｈ）の阻害化合物およびこれらの化合物を含む医薬組成物 Download PDFInfo
- Publication number
- JP2013510106A JP2013510106A JP2012537324A JP2012537324A JP2013510106A JP 2013510106 A JP2013510106 A JP 2013510106A JP 2012537324 A JP2012537324 A JP 2012537324A JP 2012537324 A JP2012537324 A JP 2012537324A JP 2013510106 A JP2013510106 A JP 2013510106A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydroxy
- indole
- carboxylic acid
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 230000002401 inhibitory effect Effects 0.000 title claims description 9
- 102000003855 L-lactate dehydrogenase Human genes 0.000 title description 23
- 108700023483 L-lactate dehydrogenases Proteins 0.000 title description 23
- 239000008194 pharmaceutical composition Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 15
- 201000004792 malaria Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 63
- 201000011510 cancer Diseases 0.000 claims description 44
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 39
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 claims description 26
- -1 trihalo-C 1-4 -alkyl Chemical group 0.000 claims description 24
- 102100034671 L-lactate dehydrogenase A chain Human genes 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 16
- 108090000790 Enzymes Proteins 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 9
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrug Drugs 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 125000001624 naphthyl group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 claims description 6
- FRNMLTUFRZNRMN-UHFFFAOYSA-N 1-hydroxy-4-(4-phenyltriazol-1-yl)indole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1N(N=N1)C=C1C1=CC=CC=C1 FRNMLTUFRZNRMN-UHFFFAOYSA-N 0.000 claims description 6
- RABDZGXLKUNVIO-UHFFFAOYSA-N 1-hydroxy-5,6-diphenylindole-2-carboxylic acid Chemical compound C=1C=CC=CC=1C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=CC=C1 RABDZGXLKUNVIO-UHFFFAOYSA-N 0.000 claims description 6
- KGMNEXZTTRCDBJ-UHFFFAOYSA-N 1-hydroxy-5-(4-methoxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(N(O)C(=C2)C(O)=O)C2=C1 KGMNEXZTTRCDBJ-UHFFFAOYSA-N 0.000 claims description 6
- RTQWCTDOAZOGRH-UHFFFAOYSA-N 1-hydroxy-5-phenylindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=CC=C1 RTQWCTDOAZOGRH-UHFFFAOYSA-N 0.000 claims description 6
- JKKGPYGQPYFSNR-UHFFFAOYSA-N 1-hydroxy-6-(4-methoxyphenyl)indole-2-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 JKKGPYGQPYFSNR-UHFFFAOYSA-N 0.000 claims description 6
- JTVQZHGFLRTDFC-UHFFFAOYSA-N 1-hydroxy-6-[3-(trifluoromethoxy)phenyl]indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=CC(OC(F)(F)F)=C1 JTVQZHGFLRTDFC-UHFFFAOYSA-N 0.000 claims description 6
- AGAPSTOEFWRRAQ-UHFFFAOYSA-N 1-hydroxy-6-[4-(trifluoromethyl)phenyl]indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=C(C(F)(F)F)C=C1 AGAPSTOEFWRRAQ-UHFFFAOYSA-N 0.000 claims description 6
- WMFMSPXVBCJHRS-UHFFFAOYSA-N 1-hydroxy-6-[methyl-[4-(trifluoromethyl)phenyl]sulfamoyl]indole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=C(C(F)(F)F)C=C1 WMFMSPXVBCJHRS-UHFFFAOYSA-N 0.000 claims description 6
- ROZRSECOCQXQFF-UHFFFAOYSA-N 1-hydroxy-6-naphthalen-2-ylindole-2-carboxylic acid Chemical compound C1=CC=CC2=CC(C3=CC=C4C=C(N(C4=C3)O)C(=O)O)=CC=C21 ROZRSECOCQXQFF-UHFFFAOYSA-N 0.000 claims description 6
- KGXDBNBXAPVUIM-UHFFFAOYSA-N 1-hydroxy-6-phenyl-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=C(C(F)(F)F)C=C1C1=CC=CC=C1 KGXDBNBXAPVUIM-UHFFFAOYSA-N 0.000 claims description 6
- JPTIDBKFQSCJSC-UHFFFAOYSA-N 1-hydroxy-6-phenylindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=CC=C1 JPTIDBKFQSCJSC-UHFFFAOYSA-N 0.000 claims description 6
- NMBOQCDQTOCORB-UHFFFAOYSA-N 6-[(4-fluorophenyl)-methylsulfamoyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=C(F)C=C1 NMBOQCDQTOCORB-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 206010025323 Lymphomas Diseases 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 6
- BALGRYSMSQXEFI-UHFFFAOYSA-N 1-hydroxy-3-methyl-6-phenyl-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C=1C(C(F)(F)F)=C2C(C)=C(C(O)=O)N(O)C2=CC=1C1=CC=CC=C1 BALGRYSMSQXEFI-UHFFFAOYSA-N 0.000 claims description 5
- QCRXVEVTMSISGH-UHFFFAOYSA-N 1-hydroxy-6-(2h-tetrazol-5-yl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C=1N=NNN=1 QCRXVEVTMSISGH-UHFFFAOYSA-N 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 239000012453 solvate Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 150000008266 deoxy sugars Chemical class 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000004761 fibrosis Effects 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 229920001542 oligosaccharide Polymers 0.000 claims description 4
- 150000002482 oligosaccharides Chemical class 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 125000005105 dialkylarylsilyl group Chemical group 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002791 glucosyl group Chemical class C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 abstract description 17
- 230000001146 hypoxic effect Effects 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 5
- 102000000428 Lactate Dehydrogenases Human genes 0.000 abstract description 4
- 108010080864 Lactate Dehydrogenases Proteins 0.000 abstract description 4
- 244000045947 parasite Species 0.000 abstract description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 184
- 238000005160 1H NMR spectroscopy Methods 0.000 description 96
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 62
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 55
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 229910002092 carbon dioxide Inorganic materials 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 33
- 238000004128 high performance liquid chromatography Methods 0.000 description 30
- 239000000203 mixture Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 108010029485 Protein Isoforms Proteins 0.000 description 18
- 102000001708 Protein Isoforms Human genes 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
- 239000003960 organic solvent Substances 0.000 description 13
- 239000002243 precursor Substances 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 12
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000012267 brine Substances 0.000 description 11
- 239000012074 organic phase Substances 0.000 description 11
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- 238000004809 thin layer chromatography Methods 0.000 description 11
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 229940076788 pyruvate Drugs 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 230000008034 disappearance Effects 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 230000034659 glycolysis Effects 0.000 description 8
- 125000002950 monocyclic group Chemical group 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 6
- DPTNMLUPFDKDAJ-UHFFFAOYSA-N 1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1 DPTNMLUPFDKDAJ-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 208000032612 Glial tumor Diseases 0.000 description 5
- 102000005548 Hexokinase Human genes 0.000 description 5
- 108700040460 Hexokinases Proteins 0.000 description 5
- 102100024580 L-lactate dehydrogenase B chain Human genes 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 4
- IHROBPZWETYCBZ-UHFFFAOYSA-N 1-hydroxybenzimidazole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=NC2=C1 IHROBPZWETYCBZ-UHFFFAOYSA-N 0.000 description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 229940107700 pyruvic acid Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 3
- XEHOTDIYIPMBKM-UHFFFAOYSA-N 1-hydroxy-5-[4-(trifluoromethyl)phenyl]indole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=C(C(F)(F)F)C=C1 XEHOTDIYIPMBKM-UHFFFAOYSA-N 0.000 description 3
- PRXFEZMUXJVPLH-UHFFFAOYSA-N 1-hydroxy-5-[methyl(phenyl)sulfamoyl]indole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(O)=O)=CC2=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 PRXFEZMUXJVPLH-UHFFFAOYSA-N 0.000 description 3
- ZXRJLQXQVVCERL-UHFFFAOYSA-N 1-hydroxy-6,7-diphenyl-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C=1C=CC=CC=1C1=C2N(O)C(C(=O)O)=CC2=C(C(F)(F)F)C=C1C1=CC=CC=C1 ZXRJLQXQVVCERL-UHFFFAOYSA-N 0.000 description 3
- TWEZFQIKZANCMW-UHFFFAOYSA-N 1-hydroxy-6-(4-phenylphenyl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C(C=C1)=CC=C1C1=CC=CC=C1 TWEZFQIKZANCMW-UHFFFAOYSA-N 0.000 description 3
- WAOQWEOCFKCHFT-UHFFFAOYSA-N 1-hydroxy-6-[4-(trifluoromethoxy)phenyl]indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=C(OC(F)(F)F)C=C1 WAOQWEOCFKCHFT-UHFFFAOYSA-N 0.000 description 3
- IIBXZDJLEPARRL-UHFFFAOYSA-N 1-hydroxy-6-[4-[methyl(phenyl)sulfamoyl]phenyl]indole-2-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(O)C(C(O)=O)=CC3=CC=2)C=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 IIBXZDJLEPARRL-UHFFFAOYSA-N 0.000 description 3
- UECBZSJONLAMBN-UHFFFAOYSA-N 1-hydroxy-6-[methyl(phenyl)sulfamoyl]indole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=CC=C1 UECBZSJONLAMBN-UHFFFAOYSA-N 0.000 description 3
- PSBMNKOWGAAPML-UHFFFAOYSA-N 1-hydroxy-6-naphthalen-1-ylindole-2-carboxylic acid Chemical compound C1=CC=C2C(C3=CC=C4C=C(N(C4=C3)O)C(=O)O)=CC=CC2=C1 PSBMNKOWGAAPML-UHFFFAOYSA-N 0.000 description 3
- MFUPOHGAQSPUSQ-UHFFFAOYSA-N 4-[4-(3-carboxyphenyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1N(N=N1)C=C1C1=CC=CC(C(O)=O)=C1 MFUPOHGAQSPUSQ-UHFFFAOYSA-N 0.000 description 3
- LTNNZHPXDNYSNJ-UHFFFAOYSA-N 5-(3-carboxyphenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=CC(C(O)=O)=C1 LTNNZHPXDNYSNJ-UHFFFAOYSA-N 0.000 description 3
- FLGHHKPARVOVOG-UHFFFAOYSA-N 5-(4-carboxytriazol-1-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1=CC=C(N(O)C(=C2)C(O)=O)C2=C1 FLGHHKPARVOVOG-UHFFFAOYSA-N 0.000 description 3
- GRTXUZYUUBIOCP-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=C(Cl)C=C1 GRTXUZYUUBIOCP-UHFFFAOYSA-N 0.000 description 3
- CLKIGKKFWNIRSM-UHFFFAOYSA-N 5-(4-fluorophenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C1=CC=C(F)C=C1 CLKIGKKFWNIRSM-UHFFFAOYSA-N 0.000 description 3
- PLJBIZGUJONGQJ-UHFFFAOYSA-N 5-[4-(2-carboxyethyl)phenyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1C1=CC=C(N(O)C(=C2)C(O)=O)C2=C1 PLJBIZGUJONGQJ-UHFFFAOYSA-N 0.000 description 3
- YVRWVKIHZCCCTD-UHFFFAOYSA-N 5-[4-(3-carboxyphenyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1N(N=N1)C=C1C1=CC=CC(C(O)=O)=C1 YVRWVKIHZCCCTD-UHFFFAOYSA-N 0.000 description 3
- GWLMJYDHCHDICI-UHFFFAOYSA-N 6-(1,3-benzodioxol-5-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2OCOC2=CC(C2=CC=C3C=C(N(C3=C2)O)C(=O)O)=C1 GWLMJYDHCHDICI-UHFFFAOYSA-N 0.000 description 3
- SAUVMCYHHBYYNJ-UHFFFAOYSA-N 6-(2,2-difluoro-1,3-benzodioxol-5-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2OC(F)(F)OC2=CC(C2=CC=C3C=C(N(C3=C2)O)C(=O)O)=C1 SAUVMCYHHBYYNJ-UHFFFAOYSA-N 0.000 description 3
- OHIAOBCBAWMYTC-UHFFFAOYSA-N 6-(2,4-dichlorophenyl)-1-hydroxy-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=C(C(F)(F)F)C=C1C1=CC=C(Cl)C=C1Cl OHIAOBCBAWMYTC-UHFFFAOYSA-N 0.000 description 3
- WVUOEXGUJLVMJP-UHFFFAOYSA-N 6-(3-carboxyphenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=CC(C(O)=O)=C1 WVUOEXGUJLVMJP-UHFFFAOYSA-N 0.000 description 3
- NJZOKNNEMJZWDV-UHFFFAOYSA-N 6-(4-chlorophenyl)-1-hydroxy-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=C(C(F)(F)F)C=C1C1=CC=C(Cl)C=C1 NJZOKNNEMJZWDV-UHFFFAOYSA-N 0.000 description 3
- CIEIETZHKWQAQA-UHFFFAOYSA-N 6-(4-chlorophenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=C(Cl)C=C1 CIEIETZHKWQAQA-UHFFFAOYSA-N 0.000 description 3
- BIBWJBAEXLGFAK-UHFFFAOYSA-N 6-(4-fluorophenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=C(F)C=C1 BIBWJBAEXLGFAK-UHFFFAOYSA-N 0.000 description 3
- JATOEDYHZVJWGM-UHFFFAOYSA-N 6-(furan-3-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C=1C=COC=1 JATOEDYHZVJWGM-UHFFFAOYSA-N 0.000 description 3
- GFLNDMXVTYBORE-UHFFFAOYSA-N 6-[(2-chlorophenyl)-methylsulfamoyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=CC=C1Cl GFLNDMXVTYBORE-UHFFFAOYSA-N 0.000 description 3
- FEPLXSDJKNQSHR-UHFFFAOYSA-N 6-[(3-chlorophenyl)-methylsulfamoyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=CC(Cl)=C1 FEPLXSDJKNQSHR-UHFFFAOYSA-N 0.000 description 3
- PMQBCZJQLOSBCK-UHFFFAOYSA-N 6-[(4-chlorophenyl)-methylsulfamoyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(C)C1=CC=C(Cl)C=C1 PMQBCZJQLOSBCK-UHFFFAOYSA-N 0.000 description 3
- GKGNPXSWKMTHOR-UHFFFAOYSA-N 6-[4-(2-carboxyethyl)phenyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 GKGNPXSWKMTHOR-UHFFFAOYSA-N 0.000 description 3
- KSRRGALDZMTKQW-UHFFFAOYSA-N 6-[4-(2-carboxyethyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(CCC(=O)O)=CN1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 KSRRGALDZMTKQW-UHFFFAOYSA-N 0.000 description 3
- PSVKTLFJZUYLTP-UHFFFAOYSA-N 6-[4-(4-carboxyphenyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1N(N=N1)C=C1C1=CC=C(C(O)=O)C=C1 PSVKTLFJZUYLTP-UHFFFAOYSA-N 0.000 description 3
- BUJUZKVSMGGEHN-UHFFFAOYSA-N 6-[4-(dimethylsulfamoyl)phenyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC(S(=O)(=O)N(C)C)=CC=C1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 BUJUZKVSMGGEHN-UHFFFAOYSA-N 0.000 description 3
- BXWZIABXOBAADS-UHFFFAOYSA-N 6-[butyl(phenyl)sulfamoyl]-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1S(=O)(=O)N(CCCC)C1=CC=CC=C1 BXWZIABXOBAADS-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 3
- 230000006538 anaerobic glycolysis Effects 0.000 description 3
- 239000003430 antimalarial agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 229960005215 dichloroacetic acid Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 230000002414 glycolytic effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 150000005846 sugar alcohols Polymers 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- BHOGDVGPKVTPAD-UHFFFAOYSA-N 1-hydroxy-3-methylindole-2-carboxylic acid Chemical compound C1=CC=C2C(C)=C(C(O)=O)N(O)C2=C1 BHOGDVGPKVTPAD-UHFFFAOYSA-N 0.000 description 2
- RHQSTHZCUWNEGJ-UHFFFAOYSA-N 1-hydroxy-3-oxidobenzimidazol-3-ium-2-carboxylic acid Chemical compound C1=CC=C2[N+]([O-])=C(C(=O)O)N(O)C2=C1 RHQSTHZCUWNEGJ-UHFFFAOYSA-N 0.000 description 2
- VHZRBRJSTLLOSZ-UHFFFAOYSA-N 1-hydroxy-4-(trifluoromethyl)indole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1C(F)(F)F VHZRBRJSTLLOSZ-UHFFFAOYSA-N 0.000 description 2
- FPEQEALHBFCSJO-UHFFFAOYSA-N 1-hydroxy-4-[4-(2-hydroxyethyl)triazol-1-yl]indole-2-carboxylic acid Chemical compound N1=NC(CCO)=CN1C1=CC=CC2=C1C=C(C(O)=O)N2O FPEQEALHBFCSJO-UHFFFAOYSA-N 0.000 description 2
- UJTYOIGIMDIZRD-UHFFFAOYSA-N 1-hydroxy-4-methylindole-2-carboxylic acid Chemical compound CC1=CC=CC2=C1C=C(C(O)=O)N2O UJTYOIGIMDIZRD-UHFFFAOYSA-N 0.000 description 2
- QRTMKFSCYUHMJH-UHFFFAOYSA-N 1-hydroxy-4-phenylindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1C1=CC=CC=C1 QRTMKFSCYUHMJH-UHFFFAOYSA-N 0.000 description 2
- QGJMHYTVILHCKE-UHFFFAOYSA-N 1-hydroxy-5-(4-phenyltriazol-1-yl)indole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1N(N=N1)C=C1C1=CC=CC=C1 QGJMHYTVILHCKE-UHFFFAOYSA-N 0.000 description 2
- NQEKCFCGDAHNTG-UHFFFAOYSA-N 1-hydroxy-5-(morpholine-4-carbonyl)indole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1C(=O)N1CCOCC1 NQEKCFCGDAHNTG-UHFFFAOYSA-N 0.000 description 2
- RLRGQOZIPLSLRN-UHFFFAOYSA-N 1-hydroxy-5-[4-(2-hydroxyethyl)triazol-1-yl]indole-2-carboxylic acid Chemical compound N1=NC(CCO)=CN1C1=CC=C(N(O)C(=C2)C(O)=O)C2=C1 RLRGQOZIPLSLRN-UHFFFAOYSA-N 0.000 description 2
- WJFAMDFHQWUSKE-UHFFFAOYSA-N 1-hydroxy-5-[methyl(phenyl)carbamoyl]indole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(O)=O)=CC2=CC=1C(=O)N(C)C1=CC=CC=C1 WJFAMDFHQWUSKE-UHFFFAOYSA-N 0.000 description 2
- YCCKLFSMSWAEDP-UHFFFAOYSA-N 1-hydroxy-6-(4-methylsulfonylphenyl)indole-2-carboxylic acid Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 YCCKLFSMSWAEDP-UHFFFAOYSA-N 0.000 description 2
- GUHNKODBCPFHFM-UHFFFAOYSA-N 1-hydroxy-6-(4-pyridin-2-yltriazol-1-yl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1N(N=N1)C=C1C1=CC=CC=N1 GUHNKODBCPFHFM-UHFFFAOYSA-N 0.000 description 2
- UWBCBKWRSYKHPO-UHFFFAOYSA-N 1-hydroxy-6-(5-oxo-2h-1,2,4-oxadiazol-3-yl)indole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=NOC(=O)N1 UWBCBKWRSYKHPO-UHFFFAOYSA-N 0.000 description 2
- YUAMQOFPYLESAA-UHFFFAOYSA-N 1-hydroxy-6-[4-(2-hydroxyethyl)triazol-1-yl]indole-2-carboxylic acid Chemical compound N1=NC(CCO)=CN1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 YUAMQOFPYLESAA-UHFFFAOYSA-N 0.000 description 2
- DNTLCACXTOIJHE-UHFFFAOYSA-N 1-hydroxy-6-[4-(oxalocarbamoyl)phenyl]indole-2-carboxylic acid Chemical compound C1=CC(C(=O)NC(=O)C(=O)O)=CC=C1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 DNTLCACXTOIJHE-UHFFFAOYSA-N 0.000 description 2
- VFQJYIBNXOXOPN-UHFFFAOYSA-N 1-hydroxy-6-[methyl(phenyl)carbamoyl]indole-2-carboxylic acid Chemical compound C=1C=C2C=C(C(O)=O)N(O)C2=CC=1C(=O)N(C)C1=CC=CC=C1 VFQJYIBNXOXOPN-UHFFFAOYSA-N 0.000 description 2
- IAUAIXWIWWWMAV-UHFFFAOYSA-N 1-hydroxyindole-2,5-dicarboxylic acid Chemical compound OC(=O)C1=CC=C2N(O)C(C(=O)O)=CC2=C1 IAUAIXWIWWWMAV-UHFFFAOYSA-N 0.000 description 2
- JOIKUYSUZYZBFI-UHFFFAOYSA-N 2-(2-acetylimino-3-hydroxy-1,3-thiazol-4-yl)acetic acid Chemical compound CC(=O)N=C1SC=C(CC(O)=O)N1O JOIKUYSUZYZBFI-UHFFFAOYSA-N 0.000 description 2
- CEULPYPXOZLXNC-UHFFFAOYSA-N 2-(2-benzoylimino-3-hydroxy-1,3-thiazol-4-yl)acetic acid Chemical compound ON1C(CC(=O)O)=CSC1=NC(=O)C1=CC=CC=C1 CEULPYPXOZLXNC-UHFFFAOYSA-N 0.000 description 2
- WLQNUBVGSODFPP-UHFFFAOYSA-N 3-[[4-(carboxymethyl)-3-hydroxy-1,3-thiazol-2-ylidene]carbamoyl]benzoic acid Chemical compound ON1C(CC(=O)O)=CSC1=NC(=O)C1=CC=CC(C(O)=O)=C1 WLQNUBVGSODFPP-UHFFFAOYSA-N 0.000 description 2
- CRMRMPNEEIXHLE-UHFFFAOYSA-N 3-ethyl-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2C(CC)=C(C(O)=O)N(O)C2=C1 CRMRMPNEEIXHLE-UHFFFAOYSA-N 0.000 description 2
- CLXIGUMXTLADAA-UHFFFAOYSA-N 4-(4-butyltriazol-1-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(CCCC)=CN1C1=CC=CC2=C1C=C(C(O)=O)N2O CLXIGUMXTLADAA-UHFFFAOYSA-N 0.000 description 2
- HDNATVFLVTWFPO-UHFFFAOYSA-N 4-[[4-(carboxymethyl)-3-hydroxy-1,3-thiazol-2-ylidene]carbamoyl]benzoic acid Chemical compound ON1C(CC(=O)O)=CSC1=NC(=O)C1=CC=C(C(O)=O)C=C1 HDNATVFLVTWFPO-UHFFFAOYSA-N 0.000 description 2
- XNCPIZZGHIDALT-UHFFFAOYSA-N 4-bromo-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1Br XNCPIZZGHIDALT-UHFFFAOYSA-N 0.000 description 2
- OXFBSGLFBDKTCE-UHFFFAOYSA-N 4-chloro-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1Cl OXFBSGLFBDKTCE-UHFFFAOYSA-N 0.000 description 2
- HSPJDDSAUSXFQW-UHFFFAOYSA-N 4-fluoro-1-hydroxyindole-2-carboxylic acid Chemical compound C1=CC=C2N(O)C(C(=O)O)=CC2=C1F HSPJDDSAUSXFQW-UHFFFAOYSA-N 0.000 description 2
- OEWNTLORBRHUMR-UHFFFAOYSA-N 5-(4-butyltriazol-1-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(CCCC)=CN1C1=CC=C(N(O)C(=C2)C(O)=O)C2=C1 OEWNTLORBRHUMR-UHFFFAOYSA-N 0.000 description 2
- MTWRWBFAZUEQLO-UHFFFAOYSA-N 5-(4-chlorophenoxy)-1-hydroxyindole-2-carboxylic acid Chemical compound C=1C=C2N(O)C(C(=O)O)=CC2=CC=1OC1=CC=C(Cl)C=C1 MTWRWBFAZUEQLO-UHFFFAOYSA-N 0.000 description 2
- NJGIKYNRIBSDEJ-UHFFFAOYSA-N 5-carbamoyl-1-hydroxyindole-2-carboxylic acid Chemical compound NC(=O)C1=CC=C2N(O)C(C(O)=O)=CC2=C1 NJGIKYNRIBSDEJ-UHFFFAOYSA-N 0.000 description 2
- KADOHORBOFJWKJ-UHFFFAOYSA-N 5-cyano-1-hydroxyindole-2-carboxylic acid Chemical compound N#CC1=CC=C2N(O)C(C(=O)O)=CC2=C1 KADOHORBOFJWKJ-UHFFFAOYSA-N 0.000 description 2
- CCLCBAJEQYYUPB-UHFFFAOYSA-N 5-fluoro-1-hydroxy-6-phenylindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC(F)=C1C1=CC=CC=C1 CCLCBAJEQYYUPB-UHFFFAOYSA-N 0.000 description 2
- DHRNTJDANPZOHR-UHFFFAOYSA-N 5-fluoro-1-hydroxyindole-2-carboxylic acid Chemical compound FC1=CC=C2N(O)C(C(=O)O)=CC2=C1 DHRNTJDANPZOHR-UHFFFAOYSA-N 0.000 description 2
- HJLOYDJCVNMQFL-UHFFFAOYSA-N 6-(4-carboxyphenyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C1=CC=C(C(O)=O)C=C1 HJLOYDJCVNMQFL-UHFFFAOYSA-N 0.000 description 2
- KMEKUNNEQWLSDF-UHFFFAOYSA-N 6-(4-carboxytriazol-1-yl)-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(C(=O)O)=CN1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 KMEKUNNEQWLSDF-UHFFFAOYSA-N 0.000 description 2
- LMDYHGZTZHKZOK-UHFFFAOYSA-N 6-(cyclopropylsulfonylcarbamoyl)-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C2N(O)C(C(=O)O)=CC2=CC=C1C(=O)NS(=O)(=O)C1CC1 LMDYHGZTZHKZOK-UHFFFAOYSA-N 0.000 description 2
- PYGVZZMLEXYYEI-UHFFFAOYSA-N 6-(dimethylcarbamoyl)-1-hydroxyindole-2-carboxylic acid Chemical compound CN(C)C(=O)C1=CC=C2C=C(C(O)=O)N(O)C2=C1 PYGVZZMLEXYYEI-UHFFFAOYSA-N 0.000 description 2
- ZKINMXQLIKPEQY-UHFFFAOYSA-N 6-(dimethylsulfamoyl)-1-hydroxyindole-2-carboxylic acid Chemical compound CN(C)S(=O)(=O)C1=CC=C2C=C(C(O)=O)N(O)C2=C1 ZKINMXQLIKPEQY-UHFFFAOYSA-N 0.000 description 2
- NIULQZWFBXECSR-UHFFFAOYSA-N 6-[4-(3-carboxypropyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound N1=NC(CCCC(=O)O)=CN1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 NIULQZWFBXECSR-UHFFFAOYSA-N 0.000 description 2
- UJZGAAJJIZUBOW-UHFFFAOYSA-N 6-[5-(3-carboxypropyl)triazol-1-yl]-1-hydroxyindole-2-carboxylic acid Chemical compound OC(=O)CCCC1=CN=NN1C1=CC=C(C=C(C(O)=O)N2O)C2=C1 UJZGAAJJIZUBOW-UHFFFAOYSA-N 0.000 description 2
- LAJOCNIJZGPWIE-UHFFFAOYSA-N 6-bromo-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C(Br)C=C2N(O)C(C(=O)O)=CC2=C1 LAJOCNIJZGPWIE-UHFFFAOYSA-N 0.000 description 2
- RUGNIZJXDDBEMK-UHFFFAOYSA-N 6-carbamoyl-1-hydroxyindole-2-carboxylic acid Chemical compound NC(=O)C1=CC=C2C=C(C(O)=O)N(O)C2=C1 RUGNIZJXDDBEMK-UHFFFAOYSA-N 0.000 description 2
- BDEKXUUKKSNYFG-UHFFFAOYSA-N 6-cyano-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C(C#N)C=C2N(O)C(C(=O)O)=CC2=C1 BDEKXUUKKSNYFG-UHFFFAOYSA-N 0.000 description 2
- KTFPNGGSUKZYOS-UHFFFAOYSA-N 6-fluoro-1-hydroxyindole-2-carboxylic acid Chemical compound C1=C(F)C=C2N(O)C(C(=O)O)=CC2=C1 KTFPNGGSUKZYOS-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 description 2
- MJELXUILFCDHAV-UHFFFAOYSA-N C=1C=C2[N+]([O-])=C(C(=O)O)N(O)C2=CC=1C1=CC=CC=C1 Chemical compound C=1C=C2[N+]([O-])=C(C(=O)O)N(O)C2=CC=1C1=CC=CC=C1 MJELXUILFCDHAV-UHFFFAOYSA-N 0.000 description 2
- 0 CC(**=C1C(C)(C)CC(C)(C)C(O)=O)N1O Chemical compound CC(**=C1C(C)(C)CC(C)(C)C(O)=O)N1O 0.000 description 2
- TZRYSIGUFZYTHT-UHFFFAOYSA-N ClC1=CC=C2[N+]([O-])=C(C(=O)O)N(O)C2=C1 Chemical compound ClC1=CC=C2[N+]([O-])=C(C(=O)O)N(O)C2=C1 TZRYSIGUFZYTHT-UHFFFAOYSA-N 0.000 description 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 2
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 2
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000053067 Pyruvate Dehydrogenase Acetyl-Transferring Kinase Human genes 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101710159466 [Pyruvate dehydrogenase (acetyl-transferring)] kinase, mitochondrial Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 235000015220 hamburgers Nutrition 0.000 description 2
- 208000007173 hereditary leiomyomatosis and renal cell cancer Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 2
- 229960003538 lonidamine Drugs 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000010627 oxidative phosphorylation Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 125000004385 trihaloalkyl group Chemical group 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006219 1-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- PTXVSDKCUJCCLC-UHFFFAOYSA-N 1-hydroxyindole Chemical compound C1=CC=C2N(O)C=CC2=C1 PTXVSDKCUJCCLC-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical group OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- YCBIMRJTLPAJFE-UHFFFAOYSA-N 3-hydroxy-2h-1,3-thiazole-2-carboxylic acid Chemical compound ON1C=CSC1C(O)=O YCBIMRJTLPAJFE-UHFFFAOYSA-N 0.000 description 1
- OKEAMBAZBICIFP-UHFFFAOYSA-N 3-oxido-2,1,3-benzoxadiazol-3-ium Chemical class C1=CC=CC2=[N+]([O-])ON=C21 OKEAMBAZBICIFP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101150072179 ATP1 gene Proteins 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 101100003366 Arabidopsis thaliana ATPA gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 125000000172 C5-C10 aryl group Chemical group 0.000 description 1
- IFTRQJLVEBNKJK-UHFFFAOYSA-N CCC1CCCC1 Chemical compound CCC1CCCC1 IFTRQJLVEBNKJK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 102100021649 Elongator complex protein 6 Human genes 0.000 description 1
- 206010049811 Extraskeletal ossification Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 208000034970 Heterotopic Ossification Diseases 0.000 description 1
- 229940122084 Hexokinase inhibitor Drugs 0.000 description 1
- 101100065219 Homo sapiens ELP6 gene Proteins 0.000 description 1
- 102000002177 Hypoxia-inducible factor-1 alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- ZCDNRPPFBQDQHR-SSYATKPKSA-N Syrosingopine Chemical compound C1=C(OC)C(OC(=O)OCC)=C(OC)C=C1C(=O)O[C@H]1[C@H](OC)[C@@H](C(=O)OC)[C@H]2C[C@@H]3C(NC=4C5=CC=C(OC)C=4)=C5CCN3C[C@H]2C1 ZCDNRPPFBQDQHR-SSYATKPKSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 101150105046 atpI gene Proteins 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- SHQNGLYXRFCPGZ-UHFFFAOYSA-N ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate Chemical compound CCOC(=O)CC1=CSC(N)=N1 SHQNGLYXRFCPGZ-UHFFFAOYSA-N 0.000 description 1
- 230000007951 extracellular acidosis Effects 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000005817 fluorobutyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 125000005816 fluoropropyl group Chemical group [H]C([H])(F)C([H])([H])C([H])([H])* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 125000006038 hexenyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- WVKIFIROCHIWAY-UHFFFAOYSA-N hydron;2-(methylamino)acetic acid;chloride Chemical compound Cl.CNCC(O)=O WVKIFIROCHIWAY-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000003367 kinetic assay Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000002583 male contraceptive agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000005981 pentynyl group Chemical group 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000002165 photosensitisation Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000005495 pyridazyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000004728 pyruvic acid derivatives Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000000637 radiosensitizating effect Effects 0.000 description 1
- 238000006476 reductive cyclization reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- KOUDKOMXLMXFKX-UHFFFAOYSA-N sodium oxido(oxo)phosphanium hydrate Chemical compound O.[Na+].[O-][PH+]=O KOUDKOMXLMXFKX-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 150000007979 thiazole derivatives Chemical class 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229950002376 tirapazamine Drugs 0.000 description 1
- QVMPZNRFXAKISM-UHFFFAOYSA-N tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011883 total knee arthroplasty Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical group CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITPI2009A000140 | 2009-11-09 | ||
| IT000140A ITPI20090140A1 (it) | 2009-11-09 | 2009-11-09 | Composto inibitore dell'enzima lattato deidrogenasi (ldh) e composizione farmaceutica che comprende tale composto |
| PCT/EP2010/006740 WO2011054525A1 (en) | 2009-11-09 | 2010-11-05 | Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013510106A true JP2013510106A (ja) | 2013-03-21 |
| JP2013510106A5 JP2013510106A5 (enExample) | 2013-12-26 |
Family
ID=42244578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537324A Pending JP2013510106A (ja) | 2009-11-09 | 2010-11-05 | 乳酸脱水素酵素（ｌｄｈ）の阻害化合物およびこれらの化合物を含む医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120309794A1 (enExample) |
| EP (1) | EP2499114A1 (enExample) |
| JP (1) | JP2013510106A (enExample) |
| CN (1) | CN102639497A (enExample) |
| AU (1) | AU2010314367A1 (enExample) |
| BR (1) | BR112012010868A2 (enExample) |
| CA (1) | CA2780136A1 (enExample) |
| EA (1) | EA201290316A1 (enExample) |
| IT (1) | ITPI20090140A1 (enExample) |
| WO (1) | WO2011054525A1 (enExample) |
| ZA (1) | ZA201203993B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016129583A1 (ja) * | 2015-02-09 | 2016-08-18 | 国立大学法人岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPI20110143A1 (it) * | 2011-12-20 | 2013-06-21 | Univ Pisa | Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti |
| WO2014115764A1 (ja) * | 2013-01-25 | 2014-07-31 | 国立大学法人岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する医薬品 |
| US9750761B2 (en) | 2014-05-21 | 2017-09-05 | University Of Rochester | LDH inhibitors as treatment for fibrosis and fibrotic-related disorders |
| FR3030516B1 (fr) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| CA3029489A1 (en) * | 2016-06-29 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 1h-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof |
| EP4306108A1 (en) * | 2022-07-11 | 2024-01-17 | Theodossis Theodossiou | 5-aminolevulinic acid, or an ester thereof for use in treatment of cancer based on the inhibition of lactate dehydrogenase |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1923481A1 (de) * | 1969-05-08 | 1970-11-12 | Hoechst Ag | Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure |
| DE2060199A1 (de) * | 1970-12-08 | 1972-07-06 | Bayer Ag | 1-Hydroxy-2-carbonamido-benzimidazol-3-oxide sowie deren Alkalisalze |
| JPS63284239A (ja) * | 1987-04-13 | 1988-11-21 | ザ・フアイヤーストーン・タイヤ・アンド・ラバー・カンパニー | ヒドロキシ−ベンズイミダゾールオキシドにより変性したゴム組成物 |
| JPH0331257A (ja) * | 1989-06-28 | 1991-02-12 | Kissei Pharmaceut Co Ltd | インドール誘導体の製造方法 |
| JPH0525140A (ja) * | 1991-07-22 | 1993-02-02 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| JPH1017548A (ja) * | 1996-07-04 | 1998-01-20 | Otsuka Chem Co Ltd | インドール−２−カルボン酸エステル誘導体及び該誘導体を有効成分とする農園芸用殺菌剤 |
| JP2008504233A (ja) * | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| JP2009020453A (ja) * | 2007-07-13 | 2009-01-29 | Fujifilm Corp | 感光性組成物、硬化性組成物、カラーフィルタ用硬化性組成物、カラーフィルタ及びその製造方法、並びに、平版印刷版原版 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2065098A (en) * | 1979-12-07 | 1981-06-24 | Erba Farmitalia | N-substituted Thiazolyl Derivatives of 7-amino- cephalosporanic Acid |
| US4950602A (en) * | 1987-02-20 | 1990-08-21 | Cornell Research Foundation, Inc. | Inhibition of lactate production by pyruvate adducts |
| US6169107B1 (en) * | 1993-04-28 | 2001-01-02 | Sumitomo Pharmaceutical Co., Ltd. | Indoloylguanidine derivatives |
| DE69533714T2 (de) | 1994-12-20 | 2005-03-24 | Unilever N.V. | Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln |
| WO1998036774A1 (en) | 1996-12-18 | 1998-08-27 | The Johns Hopkins University School Of Medicine | Method of treating a lactate dehydrogenase-a (ldh-a)-associated disorder |
| WO2006017494A2 (en) | 2004-08-02 | 2006-02-16 | Elizabeth Mazzio | Inhibition of anaerobic glucose metabolism |
| US8278436B2 (en) | 2008-07-30 | 2012-10-02 | Wisconsin Alumni Research Foundation | Glycosylated warfarin analogs and uses thereof |
-
2009
- 2009-11-09 IT IT000140A patent/ITPI20090140A1/it unknown
-
2010
- 2010-11-05 WO PCT/EP2010/006740 patent/WO2011054525A1/en not_active Ceased
- 2010-11-05 JP JP2012537324A patent/JP2013510106A/ja active Pending
- 2010-11-05 EP EP10785332A patent/EP2499114A1/en not_active Withdrawn
- 2010-11-05 BR BR112012010868A patent/BR112012010868A2/pt not_active IP Right Cessation
- 2010-11-05 US US13/508,473 patent/US20120309794A1/en not_active Abandoned
- 2010-11-05 CN CN2010800516087A patent/CN102639497A/zh active Pending
- 2010-11-05 CA CA2780136A patent/CA2780136A1/en not_active Abandoned
- 2010-11-05 AU AU2010314367A patent/AU2010314367A1/en not_active Abandoned
- 2010-11-05 EA EA201290316A patent/EA201290316A1/ru unknown
-
2012
- 2012-05-31 ZA ZA2012/03993A patent/ZA201203993B/en unknown
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1923481A1 (de) * | 1969-05-08 | 1970-11-12 | Hoechst Ag | Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure |
| DE2060199A1 (de) * | 1970-12-08 | 1972-07-06 | Bayer Ag | 1-Hydroxy-2-carbonamido-benzimidazol-3-oxide sowie deren Alkalisalze |
| JPS63284239A (ja) * | 1987-04-13 | 1988-11-21 | ザ・フアイヤーストーン・タイヤ・アンド・ラバー・カンパニー | ヒドロキシ−ベンズイミダゾールオキシドにより変性したゴム組成物 |
| JPH0331257A (ja) * | 1989-06-28 | 1991-02-12 | Kissei Pharmaceut Co Ltd | インドール誘導体の製造方法 |
| JPH0525140A (ja) * | 1991-07-22 | 1993-02-02 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| JPH1017548A (ja) * | 1996-07-04 | 1998-01-20 | Otsuka Chem Co Ltd | インドール−２−カルボン酸エステル誘導体及び該誘導体を有効成分とする農園芸用殺菌剤 |
| JP2008504233A (ja) * | 2004-04-23 | 2008-02-14 | パラテック ファーマシューティカルズ インコーポレイテッド | 転写因子調節化合物およびその使用法 |
| JP2009020453A (ja) * | 2007-07-13 | 2009-01-29 | Fujifilm Corp | 感光性組成物、硬化性組成物、カラーフィルタ用硬化性組成物、カラーフィルタ及びその製造方法、並びに、平版印刷版原版 |
Non-Patent Citations (22)
| Title |
|---|
| JPN5013001750; Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ： Ｓｅｃｔｉｏｎ Ｃ Ｖｏｌ．５, 1968, ｐ．５０４-５０７ * |
| JPN5013001751; Ｈｅｌｖｅｔｉｃａ Ｃｈｉｍｉｃａ Ａｃｔａ Ｖｏｌ．５１， Ｎｏ．７, 1968, ｐ．１６１６-１６２８ * |
| JPN5013001752; Ｓｙｎｔｈｅｓｉｓ Ｖｏｌ．１１, 1975, ｐ．７０３ * |
| JPN5013001753; Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｈｅｍｉｓｔｒｙ Ｊｏｕｒｎａｌ Ｖｏｌ．１７， Ｎｏ．１１, 1983, ｐ．７７９-７８４ * |
| JPN6015004538; Ｂｕｌｌｅｔｉｎ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ ｏｆ Ｊａｐａｎ Ｖｏｌ．４０， Ｎｏ．１１, 1967, ｐ．２７０３-２７０４ * |
| JPN6015004540; Ａｎｇｅｗａｎｄｔｅ Ｃｈｅｍｉｅ， Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｅｄｉｔｉｏｎ Ｖｏｌ．４５， Ｎｏ．３２, 2006, ｐ．５３６４-５３６８ * |
| JPN6015004541; Ｊｏｕｒｎａｌ ｏｆ Ｐｈｙｓｉｃａｌ Ｃｈｅｍｉｓｔｒｙ Ａ Ｖｏｌ．１０８， Ｎｏ．５１, 2004, ｐ．１１２４１-１１２４８ * |
| JPN6015004543; Ｎｕｃｌｅｏｓｉｄｅｓ， Ｎｕｃｌｅｏｔｉｄｅｓ ＆ Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｖｏｌ．２０， Ｎｏ．１０＆１１, 2001, ｐ．１８８１-１８８９ * |
| JPN6015004545; Ｊｏｕｒｎａｌ ｏｆ Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６６， Ｎｏ．１０, 2001, ｐ．３４７４-３４８３ * |
| JPN6015004546; Ａｕｓｔｒａｌｉａｎ Ｊｏｕｒｎａｌ ｏｆ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．４０， Ｎｏ．９, 1987, ｐ．１５２７-１５３６ * |
| JPN6015004547; Ｔｅｔｒａｈｅｄｒｏｎ Ｖｏｌ．４２， Ｎｏ．１３, 1986, ｐ．３６３１-３６３６ * |
| JPN6015004548; Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ Ｖｏｌ．３２， Ｎｏ．９, 1984, ｐ．３６７８-３６８２ * |
| JPN6015004549; Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ Ｖｏｌ．３８８， Ｎｏ．２, 1975, ｐ．２６８-２７６ * |
| JPN6015004551; Ｓｙｎｔｈｅｓｉｓ Ｖｏｌ．１１, 1972, ｐ．６０６ * |
| JPN6015004552; Ｊｏｕｒｎａｌ ｏｆ Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３７， Ｎｏ．１５, 1972, ｐ．２３７２-２３７６ * |
| JPN6015004554; Ｃｈｅｍｉｃａｌ Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．１０, 1966, ｐ．３０１-３０２ * |
| JPN6015004555; Ｃｈｅｍｉｃａｌ ＆ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｂｕｌｌｅｔｉｎ Ｖｏｌ．１２， Ｎｏ．３, 1964, ｐ．２８２-２９１ * |
| JPN6015004557; Ｊｏｕｒｎａｌ ｏｆ ｔｈｅ Ｃｈｅｍｉｃａｌ Ｓｏｃｉｅｔｙ , 1944, ｐ．６２６-６２９ * |
| JPN6015004559; Ｃｈｅｍｉｓｃｈｅ Ｂｅｒｉｃｈｔｅ Ｖｏｌ．２９, 1996, ｐ．６３９-６６５ * |
| JPN6015004560; Ｔｅｔｒａｈｅｄｒｏｎ Ｌｅｔｔｅｒｓ Ｖｏｌ．２１， Ｎｏ．３, 1980, ｐ．２８１-２８４ * |
| JPN6015004562; Ｊｏｕｒｎａｌ ｏｆ Ｏｒｇａｎｉｃ Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６４， Ｎｏ．７, 1999, ｐ．２５２０-２５２３ * |
| JPN6015004564; 日本化学雑誌 Ｖｏｌ．８６， Ｎｏ．５, 1965, ｐ．５２６-５３１ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016129583A1 (ja) * | 2015-02-09 | 2016-08-18 | 国立大学法人岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 |
| JPWO2016129583A1 (ja) * | 2015-02-09 | 2017-11-24 | 国立大学法人 岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 |
| US10350192B2 (en) | 2015-02-09 | 2019-07-16 | National University Corporation Okayama University | Lactate dehydrogenase inhibitor and antiepileptic drug containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011054525A1 (en) | 2011-05-12 |
| CA2780136A1 (en) | 2011-05-12 |
| AU2010314367A1 (en) | 2012-05-31 |
| BR112012010868A2 (pt) | 2017-02-21 |
| EA201290316A1 (ru) | 2012-10-30 |
| ITPI20090140A1 (it) | 2011-05-10 |
| CN102639497A (zh) | 2012-08-15 |
| ZA201203993B (en) | 2014-11-26 |
| EP2499114A1 (en) | 2012-09-19 |
| US20120309794A1 (en) | 2012-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510106A (ja) | 乳酸脱水素酵素（ｌｄｈ）の阻害化合物およびこれらの化合物を含む医薬組成物 | |
| CN108524482B (zh) | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 | |
| JP7469522B2 (ja) | ベンゾチアゾール類誘導体及びその使用 | |
| JPH09508924A (ja) | 置換３−アリールイデン−７−アザオキシインドール化合物及びその製造方法 | |
| EP2891649B1 (en) | Prolylhydroxylase inhibitors and methods of use | |
| WO2012070114A1 (ja) | Ｎｐｙ ｙ５受容体拮抗作用を有するスルファミド誘導体 | |
| BR112012007828B1 (pt) | compostos inibidores da xantina oxidase, processo para preparar os compostos, e, composição farmacêutica para a inibição da xantina oxidase | |
| JPWO2003103654A1 (ja) | ＮＦ−κＢ活性化阻害剤 | |
| WO2013056684A2 (zh) | 做为dhodh抑制剂的噻唑衍生物及其应用 | |
| EA009051B1 (ru) | О-замещенные гидроксиарильные производные | |
| CN105601571A (zh) | 苯并咪唑类衍生物、其制备方法和应用 | |
| EP3154982A1 (en) | Compounds comprising 1,1',2,5'-tetrahydrospiro[indole-3,2'-pyrrole]-2,5'-dione system as inhibitors p53-mdm2 protein-protein interaction | |
| JP5392924B2 (ja) | Ｎｐｙｙ５受容体拮抗作用を有する化合物 | |
| JP2004505983A (ja) | ピラゾール−チアゾール化合物、これらを含む医薬組成物、およびサイクリン依存性キナーゼの阻害のためのこれらの使用方法 | |
| EP4098647A1 (en) | Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition for suppressing cancer growth comprising same as active ingredient | |
| Duendar et al. | Synthesis of some new 1-acylthiosemicarbazides and 1, 2, 4-triazol-5-thiones, and their analgesic and anti-inflammatory activities | |
| HK1174898A (en) | Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds | |
| JP2011088833A (ja) | Ｎｐｙｙ５受容体拮抗作用を有するスルファミド誘導体 | |
| WO2017098733A1 (ja) | インドール酢酸誘導体 | |
| US20240376057A1 (en) | 2,4-dioxo-1,2,3,4-tetrahydropyrimidine derivatives and their use in the treatment of tumors | |
| WO2010060277A1 (zh) | 取代乙酰肼类衍生物及其制备方法和用途 | |
| CN102688233B (zh) | 苯并三氮唑衍生物做为rsk2抑制剂的合成及应用 | |
| WO2017098731A1 (ja) | ４－フェニル－４－オキソブタン酸誘導体 | |
| KR20050019738A (ko) | ＮＦ-κＢ 활성화 저해제 | |
| HK1138521A1 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131101 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150713 |